Potential efficacy of anti-angiogenic therapy combined with immunotherapy for advanced SMARCA4-deficient thoracic tumor: a retrospective study
The early use of ICI-based treatment may result in superior survival outcomes for these patients with SMARCA4-deficient thoracic tumors compared to other treatment modalities. Besides, ICIs combined with anti-angiogenesis therapy may be a potential first-line treatment.
Authors
- Yuqing Lou (ORCID: https://orcid.org/0000-0001-9218-2718)
- Lvkan Weng
- Rong Li (ORCID: https://orcid.org/0000-0002-1805-810X)
- Xuemei Liu (ORCID: https://orcid.org/0000-0002-2882-5798)
- Yujing Li (ORCID: https://orcid.org/0000-0001-5440-5343)
- Wei Zhang (ORCID: https://orcid.org/0000-0003-3094-9711)
- Beibei Liu (ORCID: https://orcid.org/0000-0002-8729-6590)
- Danni Wang (ORCID: https://orcid.org/0000-0002-4596-0692)
- Yanwei Zhang (ORCID: https://orcid.org/0000-0002-0230-6279)
- Xiaoping Wu (ORCID: https://orcid.org/0000-0002-9447-2935)
- Lele Zhang (ORCID: https://orcid.org/0000-0001-6617-9726)
- Wenyan Ma
- Fangfei Qian
Institutions
- Shanghai Jiao Tong University (CN)
- Shanghai Chest Hospital (CN)
- Tongren Hospital (CN)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2025-09-01
- DOI
- https://doi.org/10.21037/tlcr-2025-556
- Primary Topic
- Chromatin Remodeling and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00